Stockscreener 앱 받기
6.87
4.57%
0.30
전일 마감가:
$6.57
열려 있는:
$6.6
하루 거래량:
88,507
Relative Volume:
0.76
시가총액:
$249.64M
수익:
$18.81M
순이익/손실:
$-38.90M
주가수익비율:
-5.5066
EPS:
-1.2476
순현금흐름:
$-38.83M
1주 성능:
+3.31%
1개월 성능:
-0.29%
6개월 성능:
-12.60%
1년 성능:
+1.93%
1일 변동 폭
$6.59
$6.90
1주일 범위
$6.55
$6.98
52주 변동 폭
$3.76
$8.95
프로파운드 메디컬 Stock (PROF) Company Profile
명칭
Profound Medical Corp
전화
647-476-1350
주소
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
6.87 | 249.64M | 18.81M | -38.90M | -38.83M | -1.2476 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
프로파운드 메디컬 Stock (PROF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | Lake Street | Buy |
| 2024-07-16 | 업그레이드 | Stifel | Hold → Buy |
| 2023-11-28 | 개시 | Stifel | Hold |
| 2023-08-04 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-03-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-15 | 개시 | Jefferies | Buy |
모두보기
프로파운드 메디컬 주식(PROF)의 최신 뉴스
Why Profound Medical Corp stock is gaining today - Wealth Awesome
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medi - The National Law Review
Why Profound Medical Corp stock is rising today - Wealth Awesome
Profound Medical Corp (PROF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PROF Q1 2026 Earnings: Narrower-Than-Expected Loss Beats EstimatesTrough Earnings Signal - newsline.com
Profound Medical Corp (PROF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Profound Medical Corp (PROF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Profound Medical Corp (PROF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why Profound Medical Corp stock is sliding today - Wealth Awesome
Profound Medical Corp (PROF) Institutional Confidence - TradingKey
Profound Medical Corp (PROF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(PROF) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Profound Medical Corp. (PROF) Gains 1.89% as Key Levels Come into FocusIsland Reversal - newsline.com
Profound Medical Corp. (PROF) Edges Lower as Stock Tests Key Support LevelsBuyback Factor - newsline.com
Profound Medical Corp. (PROF) Holds Near Support as Volatility Remains LowProfit Surge Picks - newsline.com
PROF Q1 2026 Earnings: Narrower Loss Than Expected, Shares Edge LowerEarnings Weakness Phase - newsline.com
Profound Medical Corp. (PROF) Gains Nearly 4% as Bullish Momentum BuildsSMA Signal - newsline.com
Why Profound Medical Corp stock is tanking today - Wealth Awesome
How (PROF) Movements Inform Risk Allocation Models - Stock Traders Daily
Profound Medical (PROF) Edges Higher Amid Continued Trade Volume and Technical FirmnessTurnaround Stocks - The Legal Advocate
Profound Medical Q1 2026 Earnings: EPS Beats Estimates, Stock DeclinesEarnings Beat Alert - Newser
PROF Q1 2026 Earnings: EPS Surprises to the Upside, Stock Declines 2%Community Pattern Alerts - Newser
Profound Medical (PROF) Hovers Near Support Amid Modest DeclineFactor Momentum - Newser
[EFFECT] Profound Medical Corp. SEC Filing - Stock Titan
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - Yahoo Finance
Profound Medical Shareholders Back Board, Question Incentive Plan - The Globe and Mail
Telix partners with EDAP, Profound on prostate imaging tech - Investing.com UK
Profound Medical (NASDAQ: PROF) investors back board, auditor and long‑term incentive units - Stock Titan
Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies - Moomoo
Profound Medical Showcases TULSA-PRO Integration with PSMA PET Imaging for Prostate Cancer at AUA2026 - Minichart
Profound Medical Q1 earnings call highlights - MSN
How Profound Medical Corp. (PROF) Affects Rotational Strategy Timing - Stock Traders Daily
Profound Medical Highlights TULSA Advances at AUA 2026 - TipRanks
Profound Medical (NASDAQ: PROF) to highlight TULSA and PSMA PET integration at AUA2026 - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - The Manila Times
Imaging combo to sharpen prostate cancer treatment planning - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure and the Future of iMRI at AUA2026 - Investing News Network
Nearly 70% of Profound Medical shares vote to support full board slate - Stock Titan
Profound Medical Annual General and Special Meeting of Shareholders Voting Results - TMX Newsfile
TradingKey - TradingKey
Profound Medical (NASDAQ: PROF) registers 921,428 resale shares - Stock Titan
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end - MSN
Profound Medical Q1 Earnings Call Highlights - TradingView
Profound Medical revenue up 104% in Q1 2026 - Medical Buyer
Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz - The National Law Review
Earnings call transcript: Profound Medical beats Q1 2026 forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Profound Medical beats Q1 2026 forecasts - Investing.com
프로파운드 메디컬 (PROF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):